- Home
- ALVO vs AAPG Comparison
ALVO vs AAPG Comparison
Compare ALVO & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- AAPG
- Stock Information
- Founded
- ALVO 2013
- AAPG 2009
- Country
- ALVO Luxembourg
- AAPG China
- Employees
- ALVO N/A
- AAPG N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- AAPG Health Care
- Exchange
- ALVO Nasdaq
- AAPG Nasdaq
- Market Cap
- ALVO 2.5B
- AAPG 2.2B
- IPO Year
- ALVO N/A
- AAPG 2025
- Fundamental
- Price
- ALVO $11.44
- AAPG $24.40
- Analyst Decision
- ALVO Buy
- AAPG Buy
- Analyst Count
- ALVO 1
- AAPG 1
- Target Price
- ALVO $18.00
- AAPG N/A
- AVG Volume (30 Days)
- ALVO 291.4K
- AAPG 14.1K
- Earning Date
- ALVO 05-07-2025
- AAPG 06-10-2025
- Dividend Yield
- ALVO N/A
- AAPG N/A
- EPS Growth
- ALVO N/A
- AAPG N/A
- EPS
- ALVO 0.34
- AAPG N/A
- Revenue
- ALVO $587,890,000.00
- AAPG $134,352,180.00
- Revenue This Year
- ALVO $22.17
- AAPG N/A
- Revenue Next Year
- ALVO $58.38
- AAPG $389.09
- P/E Ratio
- ALVO $33.75
- AAPG N/A
- Revenue Growth
- ALVO 413.92
- AAPG 341.77
- 52 Week Low
- ALVO $7.35
- AAPG $16.50
- 52 Week High
- ALVO $14.65
- AAPG $26.55
- Technical
- Relative Strength Index (RSI)
- ALVO 68.73
- AAPG N/A
- Support Level
- ALVO $9.60
- AAPG N/A
- Resistance Level
- ALVO $11.57
- AAPG N/A
- Average True Range (ATR)
- ALVO 0.48
- AAPG 0.00
- MACD
- ALVO 0.17
- AAPG 0.00
- Stochastic Oscillator
- ALVO 85.98
- AAPG 0.00
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.